Biopharmaceutical Manufacturing, Upstream, Downstream …
Biopharmaceutical Manufacturing, Upstream, Downstream processing news. News and analysis on the clinical development and manufacture of large molecule drugs. Synaffix and BigHat Biosciences collaborate to develop AI-designed ADC. BigHat will have access to the clinical-stage ADC platform technology designed by Lonza’s Synaffix.
GE Healthcare Life Sciences becomes Cytiva
Apr 1, 2020 · GE Healthcare Life Sciences completes transition into Cytiva. As Danaher’s $21bn acquisition completes, GE Life Sciences rebrands to ‘Cytiva’ and, with the COVID-19 pandemic, its CEO tells us demand is high. In the one of the largest deals seen in the contract development and manufacturing organization (CDMO) sector, Danaher Corporation ...
New wave of potential therapies to bring ‘paradigm shift’ in COPD …
Mar 25, 2024 · According to data and analytics firm GlobalData, this new wave of potential therapies will bring a shift in the treatment paradigm for COPD. The company predicts total sales for Dupixent to reach $21.4 billion globally by 2029, and ensifentrine is forecast to record sales of $1.1 billion by 2029. Asiyah Nawab, pharma analyst at GlobalData, said ...
Building a biotech hub: Switzerland focuses on mRNA, CGT and …
Sep 8, 2021 · There are 314 biotech companies in Switzerland: broken down into 251 developers and 63 suppliers. Swiss life science exports were valued at CHF 99.1bn ($108bn USD) in 2020 and accounted for 44% of total exports. The sector has grown by a factor of 4.5 since 2000, when life sciences accounted for 17% of total exports, making it the strongest ...
Kyverna Therapeutics’ CAR-T cell therapy shows promise against ...
Jun 10, 2024 · Kyverna Therapeutics has unveiled compelling new data for its CAR T-cell therapy, KYV-101, which may revolutionize the treatment of autoimmune diseases. In a landmark study involving 50 patients, KYV-101, an autologous, fully human anti-CD19 CAR-T cell therapy, has demonstrated broad efficacy across a diverse range of autoimmune conditions.
Pharma and biopharma outsourcing strategies need to use an …
Oct 26, 2022 · But a new CPhI report on 'The Future of Outsourcing' advises against this approach. “Traditionally, outsourcing strategies were designed to help secure next stage funding, but many biotechs and small pharma companies are now entering development with more robust cash flows and the ability to plan further downstream," notes the report.
US pharma hubs: The rising stars to watch
May 4, 2022 · It picks out Texas, Los Angeles and Chicago as among the hubs to watch, while there's also plenty of activity in Washington and North Carolina. Texas’ scale, workforce and institutions have made the state a leader in biopharma innovation, cancer research and more, according to the Texas Economic Development Corporation.
Transfer of Marketing Authorisation: Mergers, mega-deals and the ...
May 23, 2023 · BPR: What is a Marketing Authorisation Transfer and what does it have to do with mergers and acquisitions in the biopharma industry? A Marketing Authorisation Transfer (MAT) is a regulatory procedure for transferring ownership …
BMS achieves FDA approval for schizophrenia drug Cobenfy
Oct 1, 2024 · Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity value that completed earlier this year. The deal has paid off as Karuna’s lead asset was approved last week by the US FDA.. Cobenfy is a combination of xanomeline, which acts on the muscarinic receptor system by activating it and trospium, which blocks the muscarinic ...
Moderna announces new vaccine candidates against Lyme disease …
Apr 12, 2023 · Pic:getty/peddlalankarameshbabu. Moderna has announced new mRNA vaccine development programs: with the Lyme disease candidate representing an expansion of the company's mRNA tech to target bacterial pathogens. These add to a vaccine portfolio that already spans across respiratory viruses and latent viruses, with five candidates in Phase 3 ...